These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26365270)

  • 1. NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?
    Merinopoulos I; Venables P; Chalmers I; Vassiliou V
    Recent Adv Cardiovasc Drug Discov; 2015; 10(1):60-4. PubMed ID: 26365270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
    Hospodar AR; Smith KJ; Zhang Y; Hernandez I
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
    Simons LA; Ortiz M; Freedman B; Waterhouse BJ; Colquhoun D
    Curr Med Res Opin; 2017 Jul; 33(7):1337-1341. PubMed ID: 28425296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].
    Helms TM; Silber S; Schäfer A; Masuhr F; Palm F; Darius H; Schrör K; Bänsch D; Bramlage P; Hankowitz J; Karle CA; Stargardt T; Weil J; Geller JC
    Herzschrittmacherther Elektrophysiol; 2016 Sep; 27(3):295-306. PubMed ID: 27576696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
    An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
    Femia G; Fetahovic T; Shetty P; Lee A
    Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
    Williams BA; Evans MA; Honushefsky AM; Berger PB
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin.
    Huang D; Wong CL; Cheng KW; Chan PH; Yue WS; Wong CK; Ho CW; Wong ICK; Chan EW; Siu CW
    Postgrad Med J; 2018 Apr; 94(1110):207-211. PubMed ID: 29459408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
    Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.